ArticleSustainable cities and society2022
A real-time web tool for monitoring and mitigating indoor airborne COVID-19 transmission risks at city scale.
Article in Sustainable cities and society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Comparative assessment of airborne infection risk tools in enclosed spaces: Implications for disease control.Infectious Disease Modelling · 2025Article
- A cross-jurisdictional comparison on residential waste collection rates during earlier waves of COVID-19.Sustainable cities and society · 2023Article
- Crowding on public transport using smart card data during the COVID-19 pandemic: New methodology and case study in Chile.Sustainable cities and society · 2023Article
- Energy efficient ventilation and indoor air quality in the context of COVID-19 - A systematic review.Renewable & sustainable energy reviews · 2023Review
- An analytical tool to support public policies and isolation barriers against SARS-CoV-2 based on mobility patterns and socio-economic aspects.Applied soft computing · 2023Article
- Influences of obstacle factors on the transmission trends of respiratory infectious diseases in indoor public places.Journal of building engineering · 2023Article
- A review on indoor airborne transmission of COVID-19- modelling and mitigation approaches.Journal of building engineering · 2023Review
- Evaluating SARS-CoV-2 airborne quanta transmission and exposure risk in a mechanically ventilated multizone office building.Building and environment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Airborne transmission of aerosols contributes to a large portion of the SARS-CoV-2 spread indoors. This study develops a real-time interactive web-based platform for the public to compare various strategies to curb indoor airborne transmission of COVID-19 in different archetype buildings at a city scale. Although many countries have started vaccination and a gradual re-opening, because of emerging new variants of the virus and the possibility of future pandemics, a lively updated tool for monitoring and mitigation of infection risk is essential. As a demonstration, we evaluated the impacts of six mitigation measures on the infection risks in various building types in a city. It shows that the same strategy could perform quite differently, depending on building types and properties. All strategies are shown to reduce the infection risk but wearing a mask and reducing exposure time are the most effective strategies in many buildings, with around 60% reduction. Doubling the minimum required outdoor air ventilation rate is not as effective as other strategies to reduce the risk. It also causes considerable penalties on energy consumption. Therefore, new building ventilation standards, control actions, and design criteria should be considered to mitigate the infection risk and save energy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.